The Wyden letter urges CMS to “conduct immediate oversight and rigorous regulatory enforcement of specific Medicare Part D program requirements for plan sponsors and their PBMs.”
WBA lowered its fiscal 2024 adjusted EPS guidance to $2.80 to $2.95 reflecting challenging pharmacy industry trends and a worse-than-expected U.S. consumer environment.